Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Fu Zhou, China Clinical Trials

A listing of Fu Zhou, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (13) clinical trials

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Differentiated Thyroid Cancer.

Phase

0.0 miles

Learn More »

Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)

To compare the effects and safety of Anlotinib with placebo in patients with Medullary Thyroid Carcinoma.

Phase

0.0 miles

Learn More »

Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)

The purpose of this study is to compare the effects and safety of Anlotinib with placebo in patients with Gastric Cancer.

Phase

0.0 miles

Learn More »

A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

In June 2017, this study was revised to expand the Phase 2 part to enroll more subjects and remove the Phase 3 part under the same protocol. A Phase 3 study will be initiated separately.

Phase

0.82 miles

Learn More »

CD123/CLL1 CAR-T Cells for R/R AML

The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study aims to assess the safety and toxicity of CD123/CLL1 CAR-T Cells to patients with relapse/refractory AML.

Phase

0.82 miles

Learn More »

ATG-F VS ATG for the Prevention of GVHD

Anti-thymocyte globulin (ATG) preparative regimen in the setting of haploidentical stem cell transplantation (haplo-HSCT) is vital for inducing immune tolerance.The study aims to compare the efficacy and safety of ATG-F vs ATG, incorporated into the preparative regimens for haplo-identical transplants.

Phase

0.82 miles

Learn More »

CART-19 Cells For MRD Positive CD19+ ALL

CART-19 cells has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients who are refractory or at highest risk of relapse as defined by MRD+ status.

Phase

0.82 miles

Learn More »

CART-19 Cells For R/R B-ALL

There are limited treatment options for relapse/refractory B-cell acute lymphoblastic leukemia(ALL). However,CART-19 cells has emerged as a powerful targeted immunotherapy for highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients with relapse/refractory B-cell ALL.

Phase

0.82 miles

Learn More »

CART-19 Cells for R/R B-cell Lymphoma

Relapsed/Refractory B Cell Lymphoma is a challenge to be treated, however,CART-19 cells could be very promosing. This study aims to assess the safety and toxicity of CART-19 cells for patients with relapse or refractory B cell lymphoma.

Phase

0.82 miles

Learn More »

Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

This is a randomized, open-label, multicenter Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locally advanced or metastatic urothelial carcinoma who have received Prior platinum-containing chemotherapy. The primary objective of the entire study is to compare rogaratinib (BAY1163877) ...

Phase

0.82 miles

Learn More »